Artificial intelligence
In this deep dive, BioSpace examines how small, medium and large companies are using artificial intelligence and machine learning to enhance their drug discovery efforts.
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise.
The biopharma industry is moving toward using AI to try to determine how well a given person would perform in a role, with applications that go beyond recruiting.
More and more companies are turning to artificial intelligence for drug safety prediction, but as with any new application of AI, experts urge caution.
High multiplexed patient-centric assays could reduce patient burden
New platforms are emerging to help biopharma companies fill their human studies more efficiently, but barriers remain to their successful implementation.
A Discussion with IQVIA’s Michelle Gyzen Sr. Director, Regulatory Affairs and Drug Development Solutions
AI and machine learning could transform drug discovery, but first, practitioners must overcome ethical challenges en route to medicines for all.
Google and Microsoft are already making inroads into drug development, but smaller biotechs focused on AI may end up leading the charge.
PRESS RELEASES